Physician profile
Meghan Jonathan
NPI 1861960122
$2,658.56
in general payments reported to CMS, 2019-2025
34 companies · $842 in 2025
The $842 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $223 · 2023: $901 · 2024: $692 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,435.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $384.89 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $383.99 | 2023-2025 | |
| Lilly USA, LLC | $301.02 | 2022-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $146.02 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $116.36 | 2022-2025 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $103.40 | 2022-2024 | |
| Lundbeck LLC | $102.25 | 2023-2025 | Rexulti |
| Abbott Laboratories | $83.60 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $76.13 | 2024-2025 | Veozah |
| Dynavax Technologies Corporation | $74.33 | 2023-2024 | Heplisav-B |
| Exact Sciences Corporation | $64.76 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.70 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $59.42 | 2022 | |
| Glaxosmithkline, LLC. | $57.98 | 2023-2024 | Arexvy, Shingrix, Bexsero |
| Idorsia Pharmaceuticals US INC | $53.31 | 2022-2023 | Quviviq |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Jonathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.